Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

5.7K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.7K
Menopause01:28

Menopause

5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Bone Remodeling01:40

Bone Remodeling

40.7K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.7K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

4.4K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.4K
Infertility in Males01:23

Infertility in Males

618
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
618

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of hypoparathyroidism (HypoPT): Position Statement of the Expert Group for Polish Society of Endocrinology - update 2026.

Endokrynologia Polska·2026
Same author

Novel aspects of biochemical assessment of bone remodeling and mineralization.

Frontiers in endocrinology·2025
Same author

Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature.

JBMR plus·2025
Same author

Persistent hypercalcaemia associated with two pathogenic variants in the <i>CYP24A1</i> gene and a parathyroid adenoma-a case report and review.

Frontiers in endocrinology·2024
Same author

Management of hypoparathyroidism: a Position Statement of the Expert Group of the Polish Society of Endocrinology.

Endokrynologia Polska·2023
Same author

Pregnancy- and lactation-related osteoporosis: an important topic also for rheumatologists.

Reumatologia·2023

Related Experiment Video

Updated: Feb 26, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.3K

Osteoporosis in men.

Waldemar Misiorowski1

  • 1Department of Endocrinology, Centre of Postgraduate Medical Education, Bielański Hospital, Warsaw, Poland.

Przeglad Menopauzalny = Menopause Review
|July 20, 2017
PubMed
Summary

Osteoporotic fractures pose a significant health risk for aging men, with hypogonadism being a key factor. Testosterone deficiency is a major cause of senile osteoporosis in men, increasing fracture risk.

Area of Science:

  • Gerontology
  • Endocrinology
  • Orthopedics

Background:

  • Osteoporotic fractures are a leading cause of morbidity and mortality in aging men, with higher mortality rates compared to women.
  • Hypogonadism is a significant risk factor for osteoporosis in men, with testosterone levels negatively correlated to fracture risk.
  • Prostate cancer treatments causing acute hypogonadism drastically increase fracture risk.

Purpose of the Study:

  • To review the risk factors and pharmacotherapy for osteoporosis in men.
  • To highlight the importance of testosterone deficiency as a primary mechanism of senile osteoporosis.
  • To discuss the efficacy and registration status of osteoporosis treatments in men.

Main Methods:

  • Literature review of risk factors for male osteoporosis.
Keywords:
fracture riskhypogonadismmale osteoporosistreatment

More Related Videos

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

12.2K
Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

25.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.3K
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

12.2K
Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

25.0K
  • Analysis of the role of hypogonadism and other factors like smoking and alcohol abuse.
  • Evaluation of pharmacotherapy options and clinical trial data for osteoporosis in men.

    • Main Results:

    • Hypogonadism is a major cause of senile osteoporosis in men.
    • Pharmacotherapy is recommended for men with osteoporotic fractures or high fracture risk (FRAX).
    • Zoledronic acid is the only drug with documented risk reduction for new fractures in men; others show comparable bone mineral density increases to postmenopausal women.

    Conclusions:

    • Osteoporosis in men requires specific consideration, particularly regarding the role of hypogonadism.
    • All men with osteoporotic fractures or high fracture risk should be considered for pharmacotherapy.
    • Further research and clinical trials are needed for osteoporosis drug registration in men.